Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease by Koser, Andras et al.
86  The Open Respiratory Medicine Journal, 2010, 4, 86-91   
 
  1874-3064/10   2010 Bentham Open 
Open Access 
Safety and Efficacy of Fluticasone Propionate/Salmeterol  
Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared  
with Fluticasone Propionate/Salmeterol Diskus in Patients  
with Chronic Obstructive Pulmonary Disease 
Andras Koser
1, Jan Westerman
2, Sanjay Sharma
3, Amanda Emmett
3 and Glenn D. Crater
*,3 
1Greenville Pharmaceutical Research, Greenville, SC 864-770-0890, USA 
2Jasper Summit Research, LLC, 1280 Summit Drive Jasper, AL 35501, USA 
3Respiratory Medicines Development Center, GlaxoSmithKline, 5 Moore Drive Research Triangle Park, NC 27709, 
USA 
Abstract:  Purpose: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol 
Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone 
Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. 
Methods: This multicenter, randomized, double-blind, 12 week study was designed to evaluate FSC MDI treatment 
responses as compared with FSC DISKUS. The primary comparison of interest was non-inferiority between the FSC MDI 
treatment group and the FSC DISKUS treatment group assessed in terms of 2-hour post-dose FEV1 change from baseline 
at endpoint. The non-inferiority criterion bound was 75mL (lower confidence limit of -75mL). Inclusion criteria: Male or 
female aged > 40, post-bronchodilator FEV1  70% predicted normal, FEV1/FVC  70% and > 10 pack years smoking 
history. Adverse events were recorded by patients throughout the study on daily diary cards. Adverse events were 
collected in eCRFs at all clinic visits and during a final follow-up phone call. 
Results: Patients (N=247) were randomized to FSC MDI (FEV1% 49.3 + 12.3, FEV1/FVC 50.5 + 10.0) and FSC DISKUS 
(FEV1% 48.4 + 11.0, FEV1/FVC 50.3 + 10.3). From an ANCOVA model the least squares (LS) mean difference (FSC 
MDI– FSC DISKUS) for the 2-hour post dose FEV1 at endpoint was -2.0mL (95% CI -64mL, 59mL). Pre-dose FEV1, 
FVC, PEF, and albuterol use were also similar between the two formulations. The most common adverse events (AE) 
during treatment were headache (8% and 6% of patients), nasopharyngitis (4% and 6%), cough (3% and 4%), and sinusitis 
(2% and 5%) for FSC MDI and FSC DISKUS, respectively. Pneumonia was recorded as an AE for 2 (2%) patients in the 
FSC DISKUS arm. 
Conclusion: This is the first study to demonstrate that FSC MDI has a similar efficacy and safety profile to FSC DISKUS 
in COPD patients. 
Keywords:  Chronic Obstructive Pulmonary Disease (COPD), Fluticasone Propionate/Salmeterol (FSC) DISKUS, HFA, 
Inhaled Corticosteroid. 
INTRODUCTION 
  Current evidence-based COPD guidelines recommend 
the use of bronchodilators or bronchodilators with inhaled 
corticosteroids (ICS) for the management of stable COPD 
[1]. Long-acting bronchodilators have been shown to provide 
consistent improvement in FEV1 (Forced Expiratory Volume 
in the first second) [2-4]. Treatment with the ICS/long-acting 
ß2-agonist combination of fluticasone propionate/salmeterol 
(FSC) at a dose of 250/50mcg twice-daily via DISKUS (FSC 
DISKUS) has been shown to result in greater improvement 
in FEV1 than corresponding doses of fluticasone propionate 
and salmeterol alone [3]. FSC DISKUS has also been shown 
to improve exercise endurance time, lung hyperinflation, and 
reduce exacerbations in patients with COPD [3, 5]. 
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  FSC is also available in inhalation aerosol formulations. 
The inhalation aerosol formulation of FSC is delivered via 
metered-dose-inhaler and is available in the following 3 
strengths (doses) expressed as drug delivered from the 
actuator: 45/21mcg (90mcg/42mcg twice-daily), 115/21mcg 
(230/42mcg twice-daily), and 230/21mcg (460/42mcg twice-
daily). FSC in the MDI is formulated with the 
hydrofluoroalkane 134a (HFA) propellant which was 
developed as a non-ozone depleting alternative to the 
chlorofluorocarbon MDI. All doses of FSC in the MDI are 
indicated for the treatment of asthma in the United States 
(US). The dose of MDI evaluated in this study was 
115/21mcg two puffs twice-daily (FSC MDI) which is 
equivalent to the 250/50mcg dose of FSC DISKUS that is 
indicated for the treatment of COPD in the US. While the 
FSC DISKUS device is widely used for the treatment of 
COPD, there may be instances when the MDI is preferred by 
the patient or when the DISKUS is not a clinical option. The FSC MDI and its Comparable Dose  The Open Respiratory Medicine Journal, 2010, Volume 4    87 
MDI device may be the only option for patients with COPD 
that have a treacheostomy or who are intubated. 
Additionally, FSC DISKUS contains lactose and is 
contraindicated in patients with significant allergic reactions 
to lactose or milk protein. The purpose of this study was to 
provide comparative information on the efficacy and safety 
of the FSC MDI and FSC DISKUS in patients with COPD. 
MATERIALS AND METHODOLOGY 
Patients 
 Inclusion  Criteria:  a) diagnosis of COPD; b) current or 
former smokers with at least a 10 pack year history; c) aged 
> 40 years; d) post-bronchodilator FEV1 of > 0.70L and < 
70% predicted normal (or if FEV1 < 0.70 L, then >40% of 
predicted normal value), and a post-albuterol FEV1/FVC 
ratio of < 0.70. 
 Exclusion  Criteria: a) current diagnosis of asthma; b) 
respiratory diagnosis considered to be significant that was 
not related to COPD; c) a clinically significant and 
uncontrolled medical disorder; d) experienced a COPD 
exacerbation/infection that required corticosteroids and/or 
antibiotics that did not resolve within 30 days of visit 1; e) a 
COPD exacerbation that resulted in hospitalization and did 
not resolve within 3 months of screening; f) abnormal and 
clinically significant 12-lead electrocardiogram (ECG) at 
screening ; g) a body mass index (BMI) cut-off > 40kg/m
2; 
h) use of nocturnal positive pressure such as continuous 
positive airway pressure or bi-level positive airway pressure 
was exclusionary. For the purposes of this study, an 
abnormal ECG was defined as a 12-lead tracing which was 
interpreted as (but not limited to) myocardial ischemia, 
clinically significant arrhythmias or left bundle branch block. 
 Study  Design:  This was a randomized, double-blind, 
double-dummy, parallel group study that was conducted at 
16 research sites in the United States. Each site received 
institutional review board or ethics committee approval for 
the study and all patients provided written informed consent. 
The patients completed an 8 -14 day run-in period on only 
short- acting ß2 agonists. Following run-in patients were 
randomized to FSC MDI twice-daily or FSC DISKUS twice-
daily for a period of 3 months. Study visits were conducted 
at screening, day 1 (randomization), and after 4, 8, and 12 
weeks of treatment. Patients were stratified based on FEV1 
response to albuterol (400g) at screening to provide a 
similar distribution of albuterol-responsive and non-
responsive patients in each group. Albuterol-responsive was 
defined as an increase in FEV1 of  200 mL and  12% from 
baseline. The use of concurrent inhaled long-acting 
bronchodilators (ß2-agonist and anticholinergic), 
ipratropium/albuterol combination products, oral ß2-agonist, 
inhaled corticosteroids, and theophylline preparations were 
not allowed during the run-in and double-blind treatment 
periods. 
 Measurements:  The primary endpoint was 2 hour post-
dose FEV1 at endpoint. Endpoint was defined as the last 2-
hour post-dose FEV1 measurement obtained during the 12-
week treatment period. Baseline was defined as the pre-dose 
FEV1 measure from Visit 2 (randomization). Secondary 
efficacy measures were AM (morning) pre-dose FEV1 and 
AM peak expiratory flow (PEF) over weeks 1-12. Other 
efficacy measures were 2 hour post-dose Forced Vital 
Capacity (FVC), AM pre-dose FVC at endpoint and 
supplemental albuterol use over weeks 1-12. AM PEF 
measurement and supplemental albuterol use was recorded 
by the patient daily on diary cards. Quality of life measures 
were not assessed in this study. 
  Safety was evaluated by recording all adverse events 
(AE’s). Adverse events were recorded by patients throughout 
the study on daily diary cards. Adverse events were collected 
in eCRFs at all clinic visits and during a final follow-up 
phone call. 
  A COPD exacerbation was defined as worsening of 
dyspnea, cough, and/or sputum beyond day-to-day 
variability requiring treatment with systemic (oral or 
parenteral); corticosteroids and/or antibiotics, and/or 
requiring hospitalization. 
 Statistical  Analysis:  The sample size for this study was 
calculated to assess non-inferiority of the FSC MDI 
treatment response to the FSC DISKUS treatment response 
for the primary efficacy endpoint of 2-hour post-dose FEV1. 
Using 75mL as the non-inferiority criterion bound (lower 
confidence limit of -75mL) and a standard deviation estimate 
of 185mL, it was estimated that a sample size of 125 patients 
per treatment group would provide approximately 90% 
power to assess non-inferiority of FSC MDI to FSC 
DISKUS based on a one-sided significance level of 2.5%. 
  The primary analysis population was the Intent-to-Treat 
(ITT) population. The ITT population included all patients 
who had been randomized to study drug. The per protocol 
population included all patients in the ITT population with 
no protocol deviations that may have impacted treatment 
response. As this study was designed to show non-
inferiority, analysis of the per protocol population was of 
importance and served as a confirmatory analysis for the 
primary analysis of the ITT population. 
  The primary efficacy analysis was mean change from 
baseline in 2-hour post-dose FEV1 compared between the 
two treatment groups at endpoint. An ANCOVA model with 
terms for treatment group, investigator, reversibility stratum 
and baseline was used to assess non-inferiority of the 
primary endpoint. ANCOVA models were also used to 
compare mean change from baseline values for the 
secondary and other efficacy measures. AM PEF measures 
and supplemental albuterol use were compared for the 
overall 12-week treatment period and spirometry measures 
were compared at endpoint. Baseline for the diary measures 
was determined from the 7-day period immediately prior to 
randomization (Visit 2) and baseline for the spirometry 
measures was defined as the pre-dose measure from 
randomization (Visit 2). Treatment group differences from 
the ANCOVA models were presented as least squares means 
and standard errors with the corresponding 95% confidence 
intervals. Statistical programming was performed in a UNIX 
environment using SAS
® Version 9.1. 
RESULTS 
  A total of 365 patients were screened of which 247 were 
randomized (121 to FSC MDI and 126 to FSC DISKUS). 
Two hundred and nine (85%) of patients completed the study 
(106 in FSC MDI and 103 in FSC DISKUS) (Fig. 1). In the 88    The Open Respiratory Medicine Journal, 2010, Volume 4  Koser et al. 
FSC MDI group 15 (12%) of the patients were withdrawn 
while in the FSC DISKUS group 23 (18%) were withdrawn 
(Fig. 1). 
  Adverse Events accounted for the main reason for 
withdrawal in both treatments FSC MDI (n=5) and FSC 
DISKUS (n=9). Demographics and clinical characteristics 
are provided in Table 1. Fifty three percent of the patients 
were male, with a mean age of 63 years (range 40-86 years) 
and a mean of 58 pack years (range 10-189 years) smoking. 
Mean (+ SD) post bronchodilator FEV1 % predicted was 
49.3% (12.3) and 48.4% (11.0) in the FSC MDI and FSC 
DISKUS groups, respectively. 
  Primary Endpoint (2 Hour Post-Dose FEV1):  The 2 
hour post-dose FEV1 at endpoint met the a priori definition 
of non-inferiority (-2mL LS mean difference, (-64, 59ml) 
95% confidence interval and non-inferiority p = 0.021). The 
mean (SE) 2 hour post-dose FEV1 for the FSC MDI group 
was 1289 (44) mL at baseline and 1446 (49.2) mL at 
endpoint. For the FSC DISKUS group the 2 hour post-dose 
FEV1 mean (SE) was 1228 (38.6) mL at baseline and 1372 
(43.8) mL at endpoint. The mean (SE) 2 hour post-dose 
FEV1 change from baseline for the FSC MDI group was 155 
(23.4) mL and 150 (21.9) mL for the FSC DISKUS arm (Fig. 
2). 
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Table 1.  Demography and Baseline Clinical Characteristics* 
 
 FSC  MDI   
(N =121) 
FSC DISKUS  
(N = 126) 
Age, yrs  61.6 (40-84)  63.4 (45-86) 
Male, n (%)  66 (55)  66 (52) 
Body Mass Index, kg/m
2  27.3 (16-39)  26.9 (15-40) 
Current Smoker, n (%)  74 (61)  78 (62) 
Pack Years- Smoking  56.2 (14-172)  60.0 (10-189) 
Race, n (%) 
 White  110 (91)  117 (93) 
 African American  10 (8)  9 (7) 
 Other  1 (<1)  0 
Lung Function, Mean (+ SD)
† 
 FEV1 (L)  1.47 (0.50)  1.39 (0.40) 
 FEV1 % Predicted  49.3 (12.3)  48.4 (11.0) 
 FEV1/FVC  50.5 (10.0)  50.3 (10.3) 
*Results represent means (Range) unless otherwise indicated. 
†Post-bronchodilator. 
  Secondary and Other Efficacy Measures: The AM pre-
dose mean FEV1 (SE) for the FSC MDI was 1365 mL (47.3) 
at endpoint. For the FSC DISKUS group the mean (SE) was 
1299 (42.9) mL at endpoint. The least squares mean (SE) 
difference was -8 (28.9). The 2 hour post-dose FVC mean 
(SE) for the FSC MDI was 2630 (74.2) mL at baseline and 
2825 (73.5) mL at endpoint. For the FSC DISKUS group the 
mean (SE) was 2486 (59.2) mL at baseline and 2720 (67.4) 
mL at endpoint. The least squares mean (SE) difference was 
-33 (49.9) mL. The AM pre-dose FVC mean (SE) for the 
FSC MDI was 2675 (72.1) mL at endpoint. For the FSC 
DISKUS group the mean (SE) was 2618 (66.3) mL at 
endpoint. The least squares mean (SE) difference was -74 
(48.1) mL. The least squares mean (SE) difference at weeks 
1-12 for supplemental albuterol use between the groups was 
0.1 (0.28) puffs per day (Table 2). The least squares mean 
(SE) difference at weeks 1-12 for AM PEF between the 
groups was 2.3 (3.55) L/min (Table 2). Improvements in the 
secondary and other efficacy measures were similar for both 
the FSC DISKUS and FSC MDI groups. Differences 
between the treatment groups were not statistically 
significant. 
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 Safety: A total of 5 (4%) and 9 (7%) patients were 
withdrawn from the study as a result of AE’s in the FSC 
MDI and FSC DISKUS groups, respectively. The most 
common AE leading to withdrawal from the study in the 
FSC MDI group was worsening of COPD 3 (2%). In the 
FSC DISKUS group worsening of COPD 2 (2%), 
pneumonia 2 (2%) and bronchitis 3 (2%) were the most 
common AEs leading to withdrawal from the study. All 
other AE’s leading to withdrawal occurred <1%. In the FSC 
MDI 45%, and 47% in the FSC DISKUS group reported any 
AE during treatment (Table 3). Candidiasis was reported by 
1 (<1%) patient in the FSC MDI treatment group and by 3 
(2%) patients in the FSC DISKUS treatment group. COPD 
exacerbations were reported for 10 (8%) patients in the FSC 
MDI group and 16 (13%) patients in the FSC DISKUS 
group. The frequency of AE’s which occurred in > 2% of 
patients in any group during treatment is provided in Table 
3. 
Table  2. Supplemental Albuterol Use and AM Peak 
Expiratory Flow at Baseline and Weeks 1-12 
 
 FSC  MDI   
(N =121) 
FSC DISKUS  
(N = 126) 
Albuterol Use, (puffs/day) Mean (SE) 
 Baseline  4.4 (0.38)  4.4 (0.34) 
 Weeks 1-12  2.4 (0.29)  2.3 (0.27) 
 LSM difference  0.1 (0.28) 
AM Peak expiratory flow, L/min Mean (SE) 
 Baseline  200.6 (7.14)  201.0 (6.20) 
 Weeks (1-12) (1-12)  222.7 (8.10)  218.0 (6.85) 
 LSM difference  2.3 (3.55) 
 
Table 3.  Summary of Adverse Events 
 
 FSC  MDI   
(N =121) 
FSC DISKUS  
(N = 126) 
AE’s occurring in >2% of patients in  
any group during treatment, n (%) 
54 (45)  59 (47) 
Any event  54 (45)  59 (47) 
Headache  10 (8)  8 (6) 
Nasopharyngtis  5 (4)  8 (6) 
Cough  4 (3)  5 (4) 
Sinusitis  3 (2)  6 (5) 
Oropharyngeal pain  5 (4)  2 (2) 
Other AE’s of interest, n (%) 
 Pneumonia  0  2 (2) 
 Eye disorders
† 0  0 
 Bone disorders
††  1 (<1)  1 (<1) 
 Death  0  0 
†Cataracts and glaucoma. 
††Foot fracture. 
 
DISCUSSION 
  Although previous randomized clinical trials (RCT) have 
demonstrated the safety and efficacy of the FSC DISKUS in 
COPD patients [3, 5-8], this is the first RCT to evaluate the 
safety and efficacy of FSC in inhalation aerosol formulation 
delivered via MDI in patients with COPD. Other studies [9-
11] have explored the efficacy and safety of these different 
formulations in asthma and were able to demonstrate that 
efficacy and safety were comparable. 
  Similarly, we found that FSC delivered via an MDI was 
as effective (non-inferiority) as when delivered via  a dry 
powder in the DISKUS based on the primary endpoint of 2-
hour post-dose FEV1. Other measures of lung function (FVC 
and PEF both pre-dose and post-dose) were also similar, 
suggesting that the different formulations have similar 
efficacy when used in a clinical trial setting. 
  With regards to safety, the incidence of adverse events, 
exacerbations, and pneumonia were similar for the two 
formulations. There were very few events in the study 
overall, a not unexpected finding given the small study size 
and the length of the trial. As in many COPD trials, 
headache and upper respiratory complaints were reported 
most commonly. Topical steroid adverse events were 
infrequent and did not occur at a frequency >2% in our trial, 
again not surprising in a trial of this size where patients were 
instructed on how to use both devices at the start of the trial. 
However, this trial was not designed to detect small 
differences in adverse events, so no definitive conclusions 
can be drawn from this data. Finally, no spacer devices were 
used in this trial and this may also have an effect on topical 
steroid side effects such as thrush and dysphonia. 
  Demonstrating efficacy can be influenced by compliance 
as well as handling of the drug delivery device. Several 
studies have compared the compliance and handling of the 
DISKUS and the MDI [12-15]. Khassawneh et al. in a 
prospective observational analysis evaluated handling of 
inhaler devices in pulmonary clinics and reported that the 
DISKUS had the lowest rate of incorrect handling while the 
MDI had the highest rate of incorrect handling [13]. We did 
not measure handling of MDI or Diskus, but the patients in 
our study did receive instructions on how to use their devices 
at each visit. 
  There are several limitations of this study. The primary 
limitation was the size and duration of the trial. This first 
study of the MDI formulation in COPD was designed to look 
for differences in effects on lung function between the active 
ingredients (fluticasone propionate and salmeterol) delivered 
via a dry powder formulation in the DISKUS and a liquid 
formulation in the MDI. A larger trial of longer duration may 
have demonstrated differences in other efficacy endpoints 
beyond lung function (e.g. exacerbations, dyspnea and 
quality of life) and in adverse events and safety endpoints. In 
addition, in this clinical trial setting, patients were instructed 
on how to use their devices at each study visit. This is 
unlikely to occur in a typical practice setting, so ease of use 
of the device and its impact on patient compliance which 
may affect efficacy must also be taken into account. 
  Finally, there has been speculation that particle size 
emitted from the device may affect the efficacy of a drug. In  
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this study, we were unable to see any differences in the 
efficacy due to the different formulations. While the 
distribution of particle size emitted from the inhalers may be 
slightly different, that did not appear to impact either the 
trough lung function (pre-dose) or the maximum lung 
function (2-hour post dose when salmeterol is at its 
maximum). 
  While the MDI formulation is not indicated for the 
treatment of COPD in the United States, it is important to 
provide clinical information on its safety and efficacy in 
patients with COPD. There may be instances in which 
COPD patients are unable to use the DISKUS or have a 
strong preference for a MDI device. The MDI device may be 
the only option for patients with COPD that have a 
treacheostomy or who are intubated. In addition, FSC 
DISKUS contains lactose and is contraindicated in patients 
with significant allergic reactions to lactose or milk protein. 
In these patients the MDI may be an option for the clinician 
to consider. 
CONCLUSION 
 This study demonstrated that the Fluticasone 
Propionate/Salmeterol Hydrofluoroalkane 134a Metered-
Dose-Inhaler 230/42mcg showed similar efficacy when 
compared with the Fluticasone Propionate/Salmeterol 
DISKUS 250/50mcg in patients with COPD. Additionally, 
this study showed the MDI and DISKUS formulations had 
similar adverse event profiles. 
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